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A commentary on
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Carotid  revascularization  with  carotid 
endarterectomy (CEA) has been shown to 
be superior to medical therapy for stroke 
prevention  in  symptomatic  and  asymp-
tomatic patients with moderate to severe 
stenosis  who  meet  well  defined  medical 
and surgical selection criteria. The ben-
efit  of  CEA  is  significantly  higher  in 
symptomatic compared to asymptomatic 
patients.  Carotid  artery  stenting  (CAS) 
has emerged as an alternative in patients 
who are considered high surgical-risk due 
to co-existent medical co-morbidities or 
anatomical  high-risk  features.  Since  its 
development in the early 1990’s, the tech-
nique of endovascular carotid revasculari-
zation has been undergoing a continuous 
maturation process mainly due to a change 
from the initial use of balloon expandable 
stents to self-expanding stents, the intro-
duction  of  and  continuously  improving 
array of emboli prevention devices (EPD’s) 
and last but not least increasing operator 
experience. This culminated in the rand-
omized SAPPHIRE trial of protected CAS 
[i.e., CAS performed with EPD] vs. CEA 
in high surgical-risk patients, that showed 
that CAS was non-inferior to CEA with 
lower peri-procedural complication rates 
as well as lower rates of restenosis (Yadav 
et al., 2004). Furthermore, increased expe-
rience with this technique has led to the 
realization that just like with CEA, there are 
patients (e.g., older age, excessive vascular 
tortuosity or calcification) who are high-
risk for CAS. (Chaturvedi et al., 2010).
The  question  of  whether  CAS  is  an 
alternative to CEA in patients without high 
surgical-risk, is addressed by the results of 
three randomized, European studies com-
paring CEA to CAS in patients without high 
surgical-risk medical or anatomical features 
(Mas et al., 2006; Ringleb et al., 2006; Ederle 
et al., 2010) (EVA-3S, SPACE, ICSS). More 
recently the North American CREST study 
results were presented at the International 
Stroke Conference in 2010 and subsequently 
published. (Brott et al., 2010). The results 
of  these  trials  were  discrepant  with  two 
(EVA-3S and ICSS; Mas et al., 2006; Ederle 
et al., 2010) showing worse outcomes with 
CAS, one failing to prove non-inferiority 
(SPACE)  (Ederle  et  al.,  2010)  and  one 
showing equivalence (CREST) (Brott et al., 
2010). Why were the results so different? To 
better understand these discrepancies, it is 
important to understand the differences in 
trial methodology.
The first and most important method-
ologic difference was operator experience 
across the four studies. In EVA 3S, opera-
tors  had  to  have  performed  at  least  five 
carotid stent procedures or be supervised 
by a physician who was qualified (Mas et al., 
2006). Following publication of the EVA3s 
manuscript it was revealed that only 16% 
of patients were treated by operators with 
more than 50 CAS cases of experience and 
39% of patients were treated by physicians in 
training (Clark, 2010). In SPACE, the opera-
tor had to have performed 25 percutaneous 
angioplasty or stent procedures, without a 
specific requirement for carotid procedures. 
Operators who had insufficient CAS experi-
ence (10 cases) could enroll patients if they 
had assistance of a tutor (Ringleb et al., 
2006). In ICSS, the requirement was 50 stent 
procedures, of which a minimum of 10 were 
required to be carotid artery procedures 
(Ederle et al., 2010). As with EVA3s and 
SPACE   inexperienced operators could have 
the assistance of a tutor. The trend across all 
of these studies is that many operators may 
have had some experience with peripheral 
stent placement but this experience was not 
necessarily acquired in the carotid arter-
ies. As aortic arch tortuosity is emerging 
as one of the critical factors determining 
procedural risk with CAS, lack of proof of 
experience with carotid catheterization as 
a prerequisite for participation in the trial 
seen across all the European studies is argu-
ably the most important factor responsible 
for the overall high rates of stroke reached in 
these studies. By contrast prospective CAS 
registries in North America, which preceded 
CREST, required a higher level of experi-
ence with brachiocephalic catheterization 
and carotid interventions and have reported 
rates of stroke that are significantly less that 
those  reported  in  the  European  studies. 
Table 1 summarizes the differences in selec-
tion criteria for stenting across the recent 
randomized trials. Site selection may also 
have been an issue; in ICSS, two centers were 
found to have an extraordinarily high rate 
of complications and were removed from 
the study after 5 of 11 patients experienced 
disabling stroke or death. The inclusion of 
inexperienced physicians and allowing them 
to perform the procedure in the presence of 
a tutor as part of a randomized trial casts 
doubt on the validity of these trials.
By  contrast  the  vetting  process  for 
the CREST study was more rigorous and 
required a minimum experience of 10–30 
carotid  stent  procedures  with  0.14′  wire 
systems, experience with EPD, and a docu-
mented  30-day  stroke  and  death  rate  of 
“6–8%”  (Hopkins  et  al.,  2010).  In  addi-
tion after admittance into the study there 
was a required lead-in phase of up to 20 
patients designed to ensure operators had 
adequate experience and acceptable compli-
cation rates prior to randomizing patients. 
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15% did not have these medications post 
procedure (Mas et al., 2006). Data regard-
ing peri-procedural anti-platelet medica-
tions were surprisingly not reported in ICSS 
(Ederle et al., 2010).
The issue of anti-platelet therapy with 
carotid  stenting  is  of  great  importance 
because following stent implantation espe-
cially within the first week there is activation 
of platelets and increases of ADP-induced 
platelet aggregation (Szapary et al., 2009). 
Vast experience from the coronary litera-
ture confirmed by carotid stenting studies 
has shown that the use of dual anti-platelet 
therapy  is  essential  in  the  prevention  of 
peri-procedural ischemic events and acute 
stent thrombosis (Bhatt et al., 2001). In the 
CREST study, the use of dual anti-platelet 
therapy was required as part of the protocol. 
An issue not addressed in any of the hitherto 
conducted studies and which requires fur-
ther study is that of   biochemical resistance to 
anti-platelet agents. The recently described 
  proceduralists performing carotid revascu-
larization were set by NASCET and ACAS, 
the first trials to show benefit of CEA com-
pared to medical therapy (North American 
Symptomatic Carotid Endarterectomy Trial, 
1991;  Endarterectomy  for  asymptomatic 
carotid artery stenosis, 1995) in which only 
experienced surgeons chosen according to 
strict criteria were allowed to participate. 
As opposed to the stenting arm operators, 
carotid  surgeons  in  the  European  rand-
omized trials of CAS vs. CEA were more 
experienced compared to their interven-
tionalist  counterparts:  no  inexperienced 
surgeon was allowed to perform the proce-
dure whether or not a tutor was present.
The second major protocol difference was 
the use of peri-procedural dual anti-  platelet 
medications. In the ICSS and EVA-3S stud-
ies, the use of dual anti-platelet medications 
was “recommended”. In EVA-3S, 17% of 
patients were not on dual anti-platelet med-
ications prior to the   procedure and nearly 
association of the cytochrome P450 2C19 
genotype to reduced effectiveness of clopi-
dogrel (Shuldiner et al., 2009) and associ-
ated cardiovascular death raises concerns 
that may be of great relevance for carotid 
stenting;  adverse  thromboembolic  events 
following carotid stenting may be reduced 
in the future by tailoring peri-procedural 
antithrombotic  agents  to  patient  specific 
response to the drug.
The third consideration was the lack of 
exclusion criteria for stenting. By contrast 
high surgical-risk criteria precluding rand-
omization were present for the CEA arms in 
all the above randomized trials. The EVA-3S 
trial did not include angiographic exclusion 
criteria for stenting, which combined with 
low operator experience, could account for 
the significant rate of perioperative stroke 
and death seen in the CAS arm, a rate not 
reported since the very first series of carotid 
stenting reported in the late 1990’s (Naylor 
et al., 1998). What has become clear is that 
Table 1 | Summary of randomized controlled studies comparing carotid artery stenting to carotid endarterecomy.
Study Number of 
patients
Endovascular 
requirements
Tutor 
Allowed
EPD use Dual anti-platelet 
use
Stent type 
used
CAS 30-day 
stroke rate
SPACE 1200 (Symptomatic 
only)
25 CAS procedures 
or at least 10 CAS 
procedures with a 
tutor
Yes 27% Mandated Wallstent, 
Precise, 
Acculink
6.5%
EVA-3S 527 (Symptomatic 
only)
At least 12 CAS 
procedures or At 
least 5 CAS 
procedures with at 
least 30 endovascular 
treatments of 
supra-aortic trunk
Yes 91% 15% of patients 
without dual therapy 
post procedure and 
17% without dual 
therapy pre-
procedure
Wallstent, 
Acculink, 
Precise, Zilver
8.8%
ICSS 1710 (symptomatic 
only)
At least 50 stent 
procedures with a 
minimum of 10 CAS
Yes 72% Recommended Interventionist 
decides
6.3%
CREST 2502(symptomatic 
[53%] and 
asymptomatic)
At least 10 CAS 
procedures with 
EPD, lead-in phase to 
demonstrate ability 
and complication rate 
of 6–8% of all cases 
performed
No Mandated Mandated Acculink 4.1%
SAPPHIRE 334 (CEA high-risk 
symptomatic 
[29%] and 
asymptomatic)
Executive Review 
Committee 
– experienced 
operators with max 
6% complication rate 
allowed
No Mandated Mandated Precise 3.6%www.frontiersin.org  July 2010  | Volume 1  | Article 14  |  3
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akin to CEA patient selection for CAS is 
key to minimizing peri-  procedural risks. 
Consistent with this experience gained from 
CEA the CREST trial had rigorous angi-
ographic exclusion criteria such as severe 
tortuosity  and  calcification,  intraluminal 
thrombi and large, bulky, plaques (Roubin 
et al., 2006), which further explains these 
discrepant results.
Fourthly,  ICSS,  EVA  3S  and  SPACE 
allowed the use of different stent and EPD 
types. By allowing operators to select the 
stent and EPD type, there may have been 
unfamiliarity with the devices particularly 
when there is a lack of consistent use. In con-
trast, the CREST study utilized one single 
stent and EPD system the Acculink™ stent 
and Accunet™ EPD (Abbott Vascular, Santa 
Clara, CA, USA) for each patient including 
for those patients treated within the lead-in 
phase. This allowed the operator to become 
familiar with the particularities of one sin-
gle device.
Lastly, a potentially critical consideration 
was the inconsistency of EPD use across all 
of the European studies. EPD’s were used in 
27%, 72% and 91% of patients in SPACE, 
ICSS and EVA 3S respectively (Mas et al., 
2006;  Ringleb  et  al.,  2006;  Ederle  et  al., 
2010).  Although  there  has  been  contro-
versy with regards to the benefit of EPD in 
preventing ischemic stroke associated with 
CAS the lack of a consistent protocol repre-
sents a significant shortcoming. The CREST 
study protocol required the use of an EPD 
for all patients enrolled. To what extent this 
requirement contributes to the lower peri-
procedural risk of stroke of 4.1% observed 
in CREST vs. 7.5–8.8% in the European 
studies is not entirely clear. Although no 
randomized  trials  have  compared  pro-
tected  CAS  vs.  unprotected  CAS,  several 
large series, including a registry compris-
ing  >12,000  patients  comparing  the  two 
approaches, have shown an approximately 
50% reduction in perioperative stroke risk 
with their use (Wholey et al., 2003). The 
ICAROS  trial  also  showed  a  significant 
reduction of events with the use of EPD 
in patients with echolucent plaques (Biasi 
et al., 2004). Although MRI based studies 
have not shown a difference in the number 
of DWI lesions when comparing protected 
to unprotected CAS, the studies were not 
powered to detect if a clinical difference 
may exist. Moreover, the use of an EPD 
may  be  a  surrogate  for  operator  experi-
ence. Despite the controversy surrounding 
EPD’s, a lack of a consistent protocol with 
regards to EPD’s likely accounts for some 
of the peri-procedural stroke rates noted 
amongst the trials.
The  inclusion  of  asymptomatic  and 
symptomatic  carotid  stenosis  patients 
in  the  CREST  and  SAPPHIRE  trials  as 
opposed to only symptomatic carotid ste-
nosis in the other trials is another impor-
tant  difference  that  raises  the  question 
regarding its contribution to the incon-
sistent results amongst the trials. Registries 
for CAS have shown differences in major 
adverse clinical event rates when compar-
ing symptomatic lesions to asymptomatic 
stenosis. The CREST trial and SAPPHIRE 
trials included 47% and 71% of patients 
respectively with asymptomatic stenosis. 
This may also account for the differences 
in the overall 30-day event rates, but does 
not  account  for  the  final  results  of  the 
North American studies compared to their 
European counterparts.
In conclusion, the CREST study showed 
non-inferiority of protected CAS to CEA. 
The  ICSS,  EVA-3S  and  SPACE  studies 
failed to reach the same conclusion due 
to higher stroke rates in the CAS group. 
For  several  reasons  outlined  above  but 
particularly because of insufficiently rig-
orous vetting standards used for carotid 
stent operators, the latter studies showed 
that  inexperienced  operators  without 
a defined protocol will achieve inferior 
results to CEA performed by experienced 
operators. Available data from CREST a 
trial with vigorous standards for operator 
experience allow us to reach the conclu-
sion that in addition to aggressive medical 
therapy there are two equivalent treatment 
options for symptomatic or asymptomatic 
carotid stenoses: CEA and protected CAS. 
Therefore, the task ahead and one that 
should be pursued in daily practice by 
endovascular specialists and carotid sur-
geons as part of multidisciplinary teams 
is to determine which procedure is best 
suited for each individual patient accord-
ing  to  patient  specific  anatomical  and 
medical considerations.
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